Prosthesis Versus Osteosynthesis in Proximal Tibia Fractures (POSITIF)

February 11, 2024 updated by: Juha Paloneva, Central Finland Hospital District

Prosthesis Versus Osteosynthesis in Treatment of Intra-articular Fractures of Proximal Tibia: A Randomized, Controlled, Trial

The aim of this study is to compare knee function and pain one year after treatment of intra-articular proximal tibia fracture using either osteosynthesis with a locking plate (ORIF) or primary total knee replacement (TKR) in patients over 65 years of age.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Intra-articular proximal tibial fractures are relatively common in the elderly. They constitute 8% of all fractures in patients over 65 years. Open reduction and internal fixation (ORIF) is the golden standard treatment for these fractures.

The treatment with ORIF is associated with significant co-morbidity due to complicating concomitant factors, such as osteoporosis, poor co-operation, infection and inadequate stability of osteosynthesis. A high failure rate (30-79 %) of fixation of tibia plateau fractures in elderly people has been reported. Most of these fractures occur in elderly persons who are at risk to lose their ability to walk independently, because of partial immobilization is required initially and full weight bearing is not allowed during 6 to 8 weeks after the operation. The risk of post-traumatic osteoarthritis has been reported to be 5.3-times higher than in the normal population even if adequate stability is achieved and other conditions normalized for fracture healing. It has also been reported that total knee replacement (TKR) performed for post-traumatic arthritis after tibial plateau fracture lead to worse outcome compared with TKR due to primary osteoarthritis. In addition, previous operations increase the risk of complications after TKR. The complication rate in secondary TKR has been reported to be over 18 %.

The available data regarding TKR as a primary treatment option for proximal tibial plateau fracture suggest that fast mobilization and return to normal daily activities may be achieved. These data also suggest a low rate of complications. There are no randomized controlled trials comparing the outcomes of the traditional treatment option (open reduction- internal fixation, ORIF) and TKR as primary treatment of these fractures. In this study investigators compare the outcomes of locking plate osteosynthesis and total knee arthroplasty according to Oxford knee score, pain, ability to walk, or quality of life one year after randomization in 98 patients aged over 65 years.

Study Type

Interventional

Enrollment (Estimated)

98

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Jyväskylä, Finland, 40620
        • Recruiting
        • Central Finland Hospital
        • Contact:
          • Juha Paloneva, MD, PhD
          • Phone Number: +358 14 2693119
        • Contact:
          • Valtteri Tapper, MD
        • Sub-Investigator:
          • Alar Toom, MD, PhD
        • Sub-Investigator:
          • Valtteri Tapper, MD, PhD
        • Principal Investigator:
          • Juha Paloneva, MD, PhD
        • Sub-Investigator:
          • Heikki Nurmi, MD, PhD
        • Sub-Investigator:
          • Maija Pesola, MD, PhD
        • Sub-Investigator:
          • Konsta Pamilo, MD, PhD
      • Kuopio, Finland
        • Not yet recruiting
        • Kuopio University Hospital
        • Contact:
          • Jussi Jalkanen, MD
        • Principal Investigator:
          • Jussi Jalkanen, MD, PhD
        • Sub-Investigator:
          • Tommi Kääriäinen, MD, PhD
      • Lahti, Finland
        • Not yet recruiting
        • Päijät-Häme Central hospital
        • Contact:
          • Jussi Haapala, MD, PhD
        • Principal Investigator:
          • Jussi Haapala, MD, PhD
        • Sub-Investigator:
          • Sami Nurmi, MD
      • Oulu, Finland
        • Not yet recruiting
        • Oulu University Hospital
        • Contact:
          • Tuukka Niinimäki, MD, PhD
        • Principal Investigator:
          • Tuukka Niinimäki, MD, PhD
        • Sub-Investigator:
          • Tero Kortekangas, MD, PhD
      • Seinäjoki, Finland
        • Not yet recruiting
        • Seinajoki Central Hospital
        • Contact:
          • Janne Jousmäki, MD, PhD
        • Principal Investigator:
          • Janne Jousmäki, MD, PhD
        • Sub-Investigator:
          • Ville Sumuvuori, MD, PhD
      • Tampere, Finland
        • Not yet recruiting
        • Tampere University Hospital
        • Contact:
          • Minna Laitinen, MD, PhD
        • Principal Investigator:
          • Ilari Pajamäki, MD
      • Tampere, Finland
        • Not yet recruiting
        • Coxa Joint Replacement Hospital
        • Contact:
          • Jyrki Nieminen, MD
        • Principal Investigator:
          • Jyrki Nieminen, MD, PhD
      • Turku, Finland
        • Not yet recruiting
        • Turku University Hospital
        • Contact:
          • Niko Strandberg, MD, PhD
        • Principal Investigator:
          • Niko Strandberg, MD, PhD
        • Sub-Investigator:
          • Mika Junnila, MD, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years and older (Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Acute intra-articular proximal tibia fracture with impression of the joint cartilage (Schatzker grades II to VI)
  • Impression of tibial plateau min 2 mm
  • Intact patellar tendon
  • The patient accepts both treatment options (osteosynthesis and arthroplasty)

Exclusion Criteria:

  • Not voluntary
  • Previous arthroplasty of the knee
  • Previous fracture affecting the knee joint
  • Inability to co-operate
  • Not independent (institutionalized living before fracture)
  • Severe osteoarthritis (Kellgren-Lawrence grade 4)
  • Open fracture (Gustilo grade 2 or over)
  • Progressive metastatic malign disease
  • Multiple fractures requiring operative treatment
  • Severe soft tissue injury around the knee (Tscherne classification grade 3)
  • Avulsion fracture of the patellar tendon or concomitant patellar tendon tear
  • Inability to walk before fracture
  • Severe medical comorbidities
  • Body Mass Index over 40
  • Unacceptably high risk of surgery due to severe medical comorbidities
  • Significant arterial or nerve trauma
  • Severe substance abuse

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: ORIF (open reduction-internal fixation)

Osteosynthesis with locking plate(s) will be performed using medial and/or lateral incision, according to morphology of the fracture. Additional osteosynthesis material will be used when necessary. The articular surface will be reduced and bone transplantation or bone substitute used if required.

Postoperatively, touch-down weight bearing will be allowed for 6 weeks, followed by 2 weeks of half-weight-bearing period. A walker or wheelchair will be used when necessary.

Osteosynthesis
Experimental: TKR (total knee replacement)
Arthroplasty of the knee will be performed within two weeks after the fracture. Medial parapatellar approach will be used. The minimal possible constraint of the prosthesis (cruciate retaining, posterior cruciate sacrificing or semi-constrained) will be used. A possible insufficient bone stock may be rebuilt with augments. Hinged prosthesis will be used only if stability of the medial collateral ligament is insufficient. A cemented or uncemented tibial stem extender (minimum length 50mm) will be used in all cases. Additional osteosynthesis will be used when necessary. Postoperatively, the patients will be allowed full weight bearing as tolerated.
Total knee arthroplasty

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Knee function
Time Frame: 12 months
Oxford knee score 12 months after randomisation
12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in knee function
Time Frame: Baseline, 6 weeks, 3 months, 6 months, 12 months, 24 months, 5 years, 10 years
Change in Oxford knee score
Baseline, 6 weeks, 3 months, 6 months, 12 months, 24 months, 5 years, 10 years
Change in pain
Time Frame: Baseline, 6 weeks, 3 months, 6 months, 12 months, 24 months, 5 years, 10 years
Numeric rating scale (rest, night, exercise)
Baseline, 6 weeks, 3 months, 6 months, 12 months, 24 months, 5 years, 10 years
Change in physical performance
Time Frame: 6 weeks (TKR only), 3 months, 6 months, 12 months, 24 months, 5 years, 10 years
Short Physical Performance Battery (SPPB)
6 weeks (TKR only), 3 months, 6 months, 12 months, 24 months, 5 years, 10 years
Change in quality of life
Time Frame: Baseline, 6 weeks, 3 months, 6 months, 12 months, 24 months, 5 years, 10 years
Short form-36 (SF-36)
Baseline, 6 weeks, 3 months, 6 months, 12 months, 24 months, 5 years, 10 years
Reoperations
Time Frame: Up to 10 years following randomisation
Need for revision surgery
Up to 10 years following randomisation
Satisfaction
Time Frame: Baseline, 6 weeks, 3 months, 6 months, 12 months, 24 months, 5 years, 10 years
Satisfaction with knee (Numeric rating scale, range 0 to 10)
Baseline, 6 weeks, 3 months, 6 months, 12 months, 24 months, 5 years, 10 years

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain medication
Time Frame: Baseline, 6 weeks, 3 months, 6 months, 12 months, 24 months, 5 years, 10 years
Pain medication used (pills per day)
Baseline, 6 weeks, 3 months, 6 months, 12 months, 24 months, 5 years, 10 years
Complications
Time Frame: Baseline, 6 weeks, 3 months, 6 months, 12 months, 24 months, 5 years, 10 years
Any complication following injury or treatment
Baseline, 6 weeks, 3 months, 6 months, 12 months, 24 months, 5 years, 10 years
Medical and social services (quantity)
Time Frame: Baseline, 6 weeks, 3 months, 6 months, 12 months, 24 months, 5 years, 10 years
Use of medical and social services (quantity)
Baseline, 6 weeks, 3 months, 6 months, 12 months, 24 months, 5 years, 10 years
Medical and social services (costs)
Time Frame: Baseline, 6 weeks, 3 months, 6 months, 12 months, 24 months, 5 years, 10 years
Costs of medical and social services used
Baseline, 6 weeks, 3 months, 6 months, 12 months, 24 months, 5 years, 10 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 9, 2018

Primary Completion (Estimated)

June 1, 2024

Study Completion (Estimated)

June 1, 2029

Study Registration Dates

First Submitted

May 22, 2017

First Submitted That Met QC Criteria

May 30, 2017

First Posted (Actual)

June 1, 2017

Study Record Updates

Last Update Posted (Estimated)

February 13, 2024

Last Update Submitted That Met QC Criteria

February 11, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Tibial Fractures

Clinical Trials on Locking plate

3
Subscribe